Immuno-Oncology | Specialty

The Ever-Changing Landscape of Myeloma Therapy

April 28th 2017

Dr. Drake Discusses Immunotherapy Agents in Bladder Cancer

April 28th 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses immunotherapy agents in bladder cancer.

Intriguing Immunotherapy Regimens Investigated in MCL

April 28th 2017

Grzegorz S. Nowakowski, MD, discusses the ever-changing landscape of mantle cell lymphoma, the intriguing combinations being studied, and the promise that immunotherapy could hold.

Dr. Papa on the Impact of CAR T Cell Trial in Head and Neck Cancer

April 27th 2017

Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses the impact of a recent study of chimeric antigen receptor (CAR) T cells in head and neck squamous cell carcinoma.

Immunotherapy Demonstrates Early Promise Across Lymphoma Subgroups

April 27th 2017

Stephen M. Ansell, MD, PhD, discusses the potential of immunotherapy agents in lymphoma, ongoing clinical trials, and where this blends in with chimeric antigen receptor (CAR) T-cell therapy.

Future Research Efforts for ALK-Driven Lung Cancer

April 27th 2017

Next Generation ALK Inhibitors for NSCLC

April 27th 2017

Treatment of ALK-Driven Refractory NSCLC

April 27th 2017

Sequencing Therapies in ALK+ NSCLC

April 27th 2017

Upfront Use of Second-Line Agents in ALK+ NSCLC

April 27th 2017

Treatment of Relapsed/Refractory ALK+ NSCLC

April 27th 2017

Repeat Mutation Testing at ALK-Rearranged NSCLC Progression

April 27th 2017

ALTA II Trial of Brigatinib in ALK-Rearranged NSCLC

April 27th 2017

FDA Approval of Brigatinib for ALK+ NSCLC

April 27th 2017

Patterns of Progression on Crizotinib for ALK+ NSCLC

April 27th 2017

The Evolution of ALK/ROS1-Targeted Therapy in NSCLC

April 27th 2017

Biomarker Testing in NSCLC to Expand in Near Future

April 26th 2017

Matthew Gubens, MD, discusses how far the field of NSCLC has come with molecular testing, the challenges still ahead, and what novel assays could be on the horizon.

Dr. Zelenetz on Nivolumab Plus Ibrutinib in Patients With CLL

April 26th 2017

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses an early-phase trial of nivolumab (Opdivo) plus ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

Dr. Socinski on Improvements to Immunotherapy for Lung Cancer

April 26th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses potential improvements to immunotherapy regimens for patients with lung cancer.

Expert Stresses Early Detection, Multidisciplinary Care for HCC

April 25th 2017

Amit Singal, MD, discusses the recent successes in the hepatocellular carcinoma treatment landscape and the challenges that still remain.